Clinical Characteristics of Post-COVID-19 Persistent Cough in the Omicron Era

다국어 초록 (Multilingual Abstract)

Cough is one of the most common symptoms of acute coronavirus disease 2019, but cough may persist for weeks or months. This study aimed to examine the clinical characteristics of patients with post-coronavirus disease (COVID) persistent cough in the Omicron era. We conducted a pooled analysis comparing 3 different groups: 1) a prospective cohort of post-COVID cough (> 3 weeks; n = 55), 2) a retrospective cohort of post-COVID cough (> 3 weeks; n = 66), and 3) a prospective cohort of non-COVID chronic cough (CC) (> 8 weeks; n = 100). Cough and health status was assessed using patient-reported outcomes (PROs). Outcomes, including PROs and systemic symptoms, were longitudinally evaluated in the prospective post-COVID cough registry participants receiving usual care. A total of 121 patients with post-COVID cough and 100 with non-COVID CC were studied. Baseline cough-specific PRO scores did not significantly differ between post-COVID cough and non-COVID CC groups. There were no significant differences in chest imaging abnormality or lung function between groups. However, the proportions of patients with fractional exhaled nitric oxide (FeNO) ≥ 25 ppb were 44.7% in those with post-COVID cough and 22.7% in those with non-COVID CC, which were significantly different. In longitudinal assessment of the post-COVID registry (n = 43), cough-specific PROs, such as cough severity or Leicester Cough Questionnaire (LCQ) scores, significantly improved between visits 1 and 2 (visit interval: median 35 [interquartile range, IQR: 23–58] days). In the LCQ score, 83.3% of the patients showed improvement (change ≥ +1.3), but 7.1% had worsened (≤ −1.3). The number of systemic symptoms was median 4 (IQR: 2–7) at visit 1 but decreased to median 2 (IQR: 0–4) at visit 2. In summary, post-COVID persistent cough was similar in overall clinical characteristics to CC. Current cough guideline-based approaches may be effective in most patients with post-COVID cough. Measurement of FeNO levels may also be useful for cough management.

참고문헌 (Reference)

• 1 Kerget B, "The role of exhaled nitric oxide(FeNO)in the evaluation of lung parenchymal involvement in COVID-19 patients" 17 : 1951-1958, 2022
• 2 Grant MC, "The prevalence of symptoms in 24, 410 adults infected by the novel coronavirus(SARS-CoV-2; COVID-19) : a systematic review and meta-analysis of 148 studies from 9 countries" 15 : e0234765-, 2020
• 3 Salem AM, "The long-term impact of COVID-19 pneumonia on the pulmonary function of survivors" 14 : 3271-3280, 2021
• 4 Kim SH, "The EQ-5D-5L valuation study in Korea" 25 : 1845-1852, 2016
• 5 Lindahl A, "Small airway function in Finnish COVID-19 survivors" 22 : 237-, 2021
• 6 Antonelli M, "Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2" 399 : 2263-2264, 2022
• 7 권재우 ; 문지용 ; 김세훈 ; 송우정 ; 김민혜 ; 강민규 ; 임경환 ; 이소희 ; 이상민 ; 이진영 ; 권혁수 ; 김경묵 ; 김상헌 ; 김상훈 ; 정재원 ; 김철우 ; 조상헌 ; 이병재, "Reliability and Validity of a Korean Version of the Leicester Cough Questionnaire" 대한천식알레르기학회 7 (7): 230-233, 2015
• 8 de Gouw HW, "Relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects" 11 : 126-132, 1998
• 9 Kim Yoonjung ; Kim Seong Eun ; 김탁 ; Yun Ki Wook ; Lee So Hee ; Lee Eunjung ; Seo Jun-Won ; Jung Young Hee ; Chong Yong Pil, "Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID" 대한감염학회 54 (54): 566-597, 2022
• 10 Carfì A, "Persistent symptoms in patients after acute COVID-19" 324 : 603-605, 2020
• 11 Ambrosino P, "Performance of fractional exhaled nitric oxide in predicting response to inhaled corticosteroids in chronic cough : a meta-analysis" 53 : 1659-1672, 2021
• 12 Vihta KD, "Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom" 76 : e133-e141, 2022
• 13 Kang YR, "Long-COVID severe refractory cough : discussion of a case with 6-week longitudinal cough characterization" 12 : e19-, 2022
• 14 송대진 ; 송우정 ; 권재우 ; 김건우 ; 김미애 ; 김미영 ; 김민혜 ; 김상하 ; 김상헌 ; 김상혁 ; 김선태 ; 김세훈 ; 김자경 ; 김주희 ; 김현정 ; 김효빈 ; 박경희 ; 윤재균 ; 이병재 ; 이승은 ; 이영목 ; 이용주 ; 임경환 ; 전유훈 ; 조은정 ; 지영구 ; 진현정 ; 최선희 ; 허규영 ; 조상헌 ; 김상훈 ; 임대현, "KAAACI Evidence-Based Clinical Practice Guidelines for Chronic Cough in Adults and Children in Korea" 대한천식알레르기학회 10 (10): 591-613, 2018
• 15 Lim S, "How to cope with emerging viral diseases : Lessons from South Korea's strategy for COVID-19, and collateral damage to cardiometabolic health" 30 : 100581-, 2023
• 16 Kang Noeul ; Won Ha-Kyeong ; Lee Ji-Hyang ; Shim Ji-Su ; Kang Sung-Yoon ; 박한기 ; Jo Eun-Jung ; Lee Seung Eun ; Kim Min-Hye ; Kim Sang-Heon ; Kim Sae-Hoon ; 장윤석 ; Lee Byung-Jae ; Song Woo-Jung ; Jo Min-Woo, "Health-Related Quality of Life and Its Determinants in Chronic Cough: The Korean Chronic Cough Registry Study" 대한천식알레르기학회 15 (15): 348-360, 2023
• 17 Lee DW, "Genomic epidemiology of SARS-CoV-2 omicron variants in the Republic of Korea" 12 : 22414-, 2022
• 18 Elfessi ZZ, "Fractional exhaled nitric oxide in normoxic adult patients with COVID-19 infection in the emergency department : a preliminary observation" 14 : 291-292, 2022
• 19 Lior Y, "Fractional exhaled Nitric Oxide(FeNO)level as a predictor of COVID-19 disease severity" 124 : 68-73, 2022
• 20 Betancor D, "Evaluation of fractional exhaled nitric oxide during SARS-CoV-2 infection" 32 : 301-303, 2022
• 21 Yelin D, "ESCMID rapid guidelines for assessment and management of long COVID" 28 : 955-972, 2022
• 22 Morice AH, "ERS guidelines on the diagnosis and treatment of chronic cough in adults and children" 55 : 1901136-, 2020
• 23 Castro M, "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma" 378 : 2486-2496, 2018
• 24 원하경 ; 강성윤 ; 강예원 ; 안 진 ; 이지향 ; 이상민 ; 권재우 ; 김민혜 ; 조은정 ; 이승은 ; 김세훈 ; 김상헌 ; 장윤석 ; 김상훈 ; 이병재 ; 조상헌 ; Surinder S. Birring ; 송우정, "Cough-Related Laryngeal Sensations and Triggers in Adults With Chronic Cough: Symptom Profile and Impact" 대한천식알레르기학회 11 (11): 622-631, 2019
• 25 Song WJ, "Confronting COVID-19-associated cough and the post-COVID syndrome : role of viral neurotropism, neuroinflammation, and neuroimmune responses" 9 : 533-544, 2021
• 26 Niyatiwatchanchai N, "Comparative study of early impacts of post-COVID-19 pneumonia on clinical manifestations, pulmonary function, and chest radiographs" 58 : 216-, 2022
• 27 Raj AA, "Clinical cough IV : what is the minimal important difference for the Leicester Cough Questionnaire?" 187 : 311-320, 2009
• 28 Maniscalco M, "Can FeNO be a biomarker in the post-COVID-19 patients monitoring?" 193 : 106745-, 2022
• 29 Cameli P, "Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae : a pivotal study" 10 : 1350-, 2021